Lexaria Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Lexaria Bioscience Corp
LEXX Stock  USD 0.81  0  0.49%   
Lexaria Bioscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lexaria Bioscience's valuation are provided below:
Gross Profit
522 K
Market Capitalization
20.3 M
Enterprise Value Revenue
32.2447
Revenue
522 K
Earnings Share
(0.57)
We have found one hundred twenty available fundamental ratios for Lexaria Bioscience, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Lexaria Bioscience last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 120.9 M in 2026. Enterprise Value is likely to rise to about 122.2 M in 2026

Lexaria Bioscience Total Revenue

426,928

Check Lexaria Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexaria Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 190.8 K, Interest Expense of 107 K or Total Revenue of 426.9 K, as well as many indicators such as Price To Sales Ratio of 110, Dividend Yield of 0.0 or PTB Ratio of 57.61. Lexaria financial statements analysis is a perfect complement when working with Lexaria Bioscience Valuation or Volatility modules.
  
Build AI portfolio with Lexaria Stock
Check out the analysis of Lexaria Bioscience Correlation against competitors.

Lexaria Bioscience Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets4.3 M4.8 M4.1 M
Slightly volatile
Total Current Liabilities1.4 M1.3 M661.1 K
Pretty Stable
Total Stockholder Equity3.6 M3.4 M3.6 M
Slightly volatile
Property Plant And Equipment Net286.4 K301.5 K843.8 K
Slightly volatile
Accounts Payable1.6 M1.6 M391.9 K
Slightly volatile
Cash1.9 M2.1 M2.3 M
Slightly volatile
Non Current Assets Total604.3 K636.1 K1.1 M
Slightly volatile
Cash And Short Term Investments2 M2.3 M2.4 M
Slightly volatile
Common Stock Total Equity95.1 K90.6 K62.4 K
Slightly volatile
Common Stock Shares Outstanding21.7 M20.7 M7.6 M
Slightly volatile
Liabilities And Stockholders Equity4.3 M4.8 M4.1 M
Slightly volatile
Non Current Liabilities Total67.5 K71 K62.1 K
Slightly volatile
Other Current Assets1.4 M1.3 M478.6 K
Slightly volatile
Other Stockholder Equity80.3 M76.5 M33.5 M
Slightly volatile
Total Liabilities1.5 M1.4 M712.3 K
Pretty Stable
Property Plant And Equipment Gross1.3 M813.4 K870.3 K
Pretty Stable
Total Current Assets2.5 M4 M3 M
Slightly volatile
Short Term Debt26 K27.4 K368.5 K
Slightly volatile
Common Stock28 K22.5 K28.7 K
Pretty Stable
Short and Long Term Debt Total93.5 K98.4 K414.3 K
Slightly volatile
Net Receivables444.8 K423.6 K207 K
Slightly volatile
Intangible Assets299.8 K354 K223.5 K
Slightly volatile
Net Tangible Assets5.5 M8.6 M4.9 M
Slightly volatile
Net Invested Capital5.6 M3.4 M4.3 M
Slightly volatile
Net Working Capital2.2 M2.3 M3.5 M
Pretty Stable
Property Plant Equipment372.5 K423.1 K231.9 K
Slightly volatile
Short Term Investments223 K190.2 K123.9 K
Slightly volatile
Capital Stock30 K17.6 K51.5 K
Slightly volatile
Long Term Debt24.5 K27.6 K30.1 K
Slightly volatile
Capital Lease Obligations123.8 K125.7 K120.8 K
Pretty Stable
Short and Long Term Debt6.3 K7.1 K7.8 K
Slightly volatile

Lexaria Bioscience Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue426.9 K635.3 K461.1 K
Very volatile
Other Operating Expenses14.9 M14.2 M5.4 M
Slightly volatile
Cost Of Revenue101.4 K106.7 K249.4 K
Slightly volatile
Total Operating Expenses14.8 M14.1 M5.1 M
Slightly volatile
Selling General Administrative5.2 M5 M3 M
Slightly volatile
Selling And Marketing Expenses145.7 K234.9 K195.4 K
Slightly volatile
Research Development9.9 M9.5 M2.3 M
Slightly volatile
Reconciled Depreciation94.8 K101 K57.7 K
Slightly volatile

Lexaria Bioscience Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation80 K79 K79.8 K
Very volatile
Capital Expenditures21.1 K22.2 K186.4 K
Slightly volatile
End Period Cash Flow1.9 M2.1 M2.3 M
Slightly volatile
Begin Period Cash Flow7.8 M7.5 M2.9 M
Slightly volatile
Stock Based Compensation561.1 K988.4 K637.2 K
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio110105171
Slightly volatile
PTB Ratio57.6154.870112.3808
Slightly volatile
Days Sales Outstanding25.0326.3466440
Slightly volatile
Book Value Per Share0.07760.08160.7305
Very volatile
Average Payables65.3 K68.7 K193.7 K
Slightly volatile
Stock Based Compensation To Revenue0.710.7486.6057
Slightly volatile
Capex To Depreciation2.5 K2.4 K299
Slightly volatile
PB Ratio57.6154.870112.3808
Slightly volatile
EV To Sales111106159
Slightly volatile
Payables Turnover8.088.52.7946
Slightly volatile
Research And Ddevelopement To Revenue11.0310.57.0121
Pretty Stable
Capex To Revenue0.07930.08351.0781
Slightly volatile
Cash Per Share0.00240.00250.5093
Very volatile
Days Payables Outstanding40.7942.941786
Slightly volatile
Intangibles To Total Assets0.05850.06640.0669
Slightly volatile
Net Debt To EBITDA4.334.12040.9549
Slightly volatile
Current Ratio0.09820.103417.5549
Very volatile
Tangible Book Value Per Share0.07760.08160.685
Very volatile
Receivables Turnover7.0413.85382.2347
Slightly volatile
Shareholders Equity Per Share0.07760.08160.7812
Very volatile
Debt To Equity0.410.60850.135
Pretty Stable
Capex Per Share0.00340.00360.0334
Pretty Stable
Average Receivables232.4 K221.4 K185.6 K
Slightly volatile
Revenue Per Share0.04060.04270.053
Pretty Stable
Interest Debt Per Share0.05710.06010.0284
Pretty Stable
Debt To Assets0.190.35740.0742
Slightly volatile
Operating Cycle25.0326.34661.2 K
Slightly volatile
Price Book Value Ratio57.6154.870112.3808
Slightly volatile
Days Of Payables Outstanding40.7942.941786
Slightly volatile
Company Equity Multiplier1.551.70251.1589
Slightly volatile
Long Term Debt To Capitalization0.120.230.1335
Slightly volatile
Total Debt To Capitalization0.20.37830.0998
Very volatile
Debt Equity Ratio0.410.60850.135
Pretty Stable
Quick Ratio0.09820.103416.3859
Very volatile
Net Income Per E B T0.781.00930.9439
Slightly volatile
Cash Ratio0.0440.046312.7621
Very volatile
Days Of Sales Outstanding25.0326.3466440
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.840.71461.0051
Slightly volatile
Price To Book Ratio57.6154.870112.3808
Slightly volatile
Fixed Asset Turnover0.30.320228.8757
Pretty Stable
Debt Ratio0.190.35740.0742
Slightly volatile
Price Sales Ratio110105171
Slightly volatile
Asset Turnover0.320.30710.0929
Slightly volatile
Price Fair Value57.6154.870112.3808
Slightly volatile

Lexaria Bioscience Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap120.9 M115.2 M25.4 M
Slightly volatile
Enterprise Value122.2 M116.4 M23.5 M
Slightly volatile

Lexaria Fundamental Market Drivers

Lexaria Upcoming Events

12th of April 2024
Upcoming Quarterly Report
View
12th of July 2024
Next Financial Report
View
29th of February 2024
Next Fiscal Quarter End
View
19th of November 2024
Next Fiscal Year End
View
30th of November 2023
Last Quarter Report
View
31st of August 2023
Last Financial Announcement
View

About Lexaria Bioscience Financial Statements

Lexaria Bioscience investors use historical fundamental indicators, such as Lexaria Bioscience's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexaria Bioscience. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue4.5 K4.7 K
Total Revenue635.3 K426.9 K
Cost Of Revenue106.7 K101.4 K
Stock Based Compensation To Revenue 0.75  0.71 
Research And Ddevelopement To Revenue 10.50  11.03 
Capex To Revenue 0.08  0.08 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue 0.27  0.28 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HITIHigh Tide
HITIHigh Tide
BACBank of America

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY